title: [Modulation of indications of adjuvant hormone therapy with tamoxifen in T1T2/N0N1 breast cancers. Preliminary results of a multicenter study with 695 cases].
abstract: From 1982 to 1990, patients less than 75 years, without any previous or synchonous carcinoma, suffering from an invasive breast cancer classified as T1T2/N0N1/MO according to clinical TNM staging, were enrolled in this study; 82.4% underwent a breast conservative procedure and 17.2% a modified radical mastectomy followed by a postoperative irradiation. Histological axillary lymph node status, Scarff-Bloom grade and/or cytological grade, estradiol receptor content, were used to define three groups of patients. The breakdown of patients is not well balanced: 416 women were included in group I (N-, grade I II, ER+) when there was no adjuvant medical treatment, 110 in group II (N-, grade III, ER+), 169 in group III (N+ < or = 3, grade I II, ER+). Patients from the latter two groups were receiving tamoxifene, 20 mg per day for 2 years; Those women not menopaused received first a pelvic irradiation. With a median follow-up of 35 months (1-138) the overall survival is respectively for the three groups 95%, 96%, 96% (P = 0.5) and the disease free survival 86%, 93%, 90% (P = 0.1). The actuarial local regional remission rate is 94%, 97%, 99% (P = 0.07). Such results need to be updated with a longer follow-up, but they show the ability of adjuvant hormonotherapy to tailor the short term survival thanks to prognostic factors.
authors.affiliation: Comité de gynécologie, unité de concertation, CHU de Grenoble, France.
authors.forename: M
authors.initials: M
authors.lastname: Bolla
authors.forename: M
authors.initials: M
authors.lastname: Mousseau
authors.forename: P
authors.initials: P
authors.lastname: Winckel
authors.forename: J
authors.initials: J
authors.lastname: Marron-Charrière
authors.forename: M
authors.initials: M
authors.lastname: Colonna
authors.forename: D
authors.initials: D
authors.lastname: Pasquier
authors.forename: M
authors.initials: M
authors.lastname: Chédin
authors.forename: M H
authors.initials: MH
authors.lastname: Panh
authors.forename: D
authors.initials: D
authors.lastname: Seigneurin
authors.forename: J
authors.initials: J
authors.lastname: Salvat
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D013629:Tamoxifen
vernacular_title: Modulation des indications de l'hormonothérapie adjuvante par le tamoxifène dans les cancers du sein T1T2/N0N1. Résultats préliminaires d'une étude multicentrique de 695 cas.